LuminUltra Acquires Legionella Testing Business from Genomadix and Inks Strategic License to Commercialize Additional Tests for Ultra-portable Molecular Diagnostic Platform
9.9.2024 14:00:00 EEST | Business Wire | Press release
LuminUltra (luminultra.com), the global leader in applied molecular diagnostics, today announced the acquisition of the legionella testing business assets of Genomadix Inc (genomadix.com), along with rights to develop and commercialize further assays and test methods in water, energy and food and beverage markets globally using the Genomadix Cube™ qPCR (quantitative polymerase chain reaction) Platform.
With this transaction, LuminUltra further expands its industry-leading portfolio of molecular testing solutions for rapid identification and quantification of the microbes within residential, commercial and industrial water systems that are responsible for causing the potentially deadly Legionnaire’s disease.
When paired with its easy-to-use automated test kit, the Genomadix Cube thermocycling platform will generate results that measure the presence and quantity of Legionella contamination in under one hour with laboratory-grade sensitivity. The elegant simplicity of the system allows any user in the field to quickly and accurately assess the level of contamination within their water system and take the actions necessary to minimize risk of outbreaks and operational downtime.
The industry leading legionella detection toolkit
“With this latest addition to our portfolio, we can now help even more customers around the world to rapidly and accurately monitor and manage against the proliferation of harmful Legionella bacteria,” said Pat Whalen, LuminUltra CEO. “This rapid, point of use solution complements our existing GeneCount® laboratory qPCR workflow and mail-in sample testing offerings by providing a best-in-class solution for those time sensitive, ‘in-field’ use cases that demand near-real-time and accurate results to confidently inform critical operational decisions and actions.”
Steve Edgett, CEO of Genomadix, added, “LuminUltra was the perfect home for the Legionella business that we nurtured under the Spartan Bioscience brand. We intend to support a seamless transition with our customers. We are thrilled that LuminUltra will bring scale, expertise, and focus to the Legionella business. Genomadix is focused on the development and commercialization of precision medicine tests on the Cube and licensing our CubeX Open Platform to strategic partners. This agreement is a win-win as LuminUltra will lead the development of new tests and expanded access to fast and accurate qPCR testing on CubeX for time-sensitive point of use applications in applied markets.”
The transaction was completed on July 31, 2024.
About LuminUltra
Founded in 1995, LuminUltra is a biological diagnostic testing company headquartered in Canada with operations in six countries. Widely recognized as the global leader in applied molecular diagnostics for the water, energy and food & beverage markets, it was also a key supplier of COVID-19 clinical testing reagents to the Government of Canada. Customers in over 80 countries trust LuminUltra’s technology, production reliability and history of customer service excellence to deliver their essential services in a safe-state. At the same time, LuminUltra fosters a culture of innovation and agility and is on an accelerated growth path, acquiring multiple companies in recent years and forming a partnership with the specialized private equity firm XPV Water Partners.
About Genomadix
Based in Ottawa, Canada, Genomadix Inc. is a pioneer in real-time qPCR point of need technology. The Genomadix Cube is a molecular diagnostic instrument capable of performing tests for precision medicine genotyping on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour. The Cube platform is also available as an open platform called CubeX that can be used to design, develop and run any qPCR test for research and product development use. Applications of the Genomadix Cube technology include but are not limited to precision medicine, clinical and environmental. For more information, visit www.genomadix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909727336/en/
Contacts
Media: Gene Schilling, Director of Marketing
gene.schilling@luminultra.com +1-519-990-0084
Media: Chelsey Martellacci, Marketing Manager
media@genomadix.com 1-888-810-7788
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Appoints Guy House as SVP, Treaty Reinsurance27.10.2026 11:00:00 EET | Press release
The Fortegra Group, Inc. ("Fortegra" or the "Company"), a global specialty insurer and part of DB Insurance Co., Ltd., has appointed Guy House as Senior Vice President, Treaty Reinsurance. In this role, he will lead Fortegra’s treaty reinsurance underwriting strategy from the Company’s UK office. Mr. House brings more than 18 years of London market experience. He has written and bought reinsurance across multiple product lines and tiers, including property, marine, energy, terrorism and aviation. His expertise spans treaty and retrocession reinsurance, direct and facultative (D&F) insurance, exposure management, alongside capital raising and management. Previously, Mr. House was Head of Property at Tamesis Dual, having joined from Markel International where he worked as the Senior Property D&F Underwriter. He is ACII qualified and holds a degree in Economics from Durham University. About Fortegra For more than 45 years, Fortegra, via its subsidiaries, has underwritten risk management s
TetraMem Advances Analog In-Memory Computing with Tapeout of New 12nm AI SoC27.10.2026 10:41:00 EET | Press release
TetraMem, a Silicon Valley-based pioneer in analog in-memory computing (A-IMC), announced the successful tapeout of MLX300, the world’s first 12nm A-IMC system-on-chip (SoC) based on multi-level RRAM technology. The SoC was developed using industry-leading EDA solutions enabled through Synopsys Cloud FlexEDA, and this milestone represents a major step in bringing this architecture toward advanced-node, production-ready computing. “TetraMem’s architecture represents a fundamentally new approach to AI computing by converging memory and compute together,” said Glenn Ge, CEO and Co-founder of TetraMem. “Leveraging Synopsys EDA solutions through Synopsys Cloud have been instrumental in enabling efficient global collaboration and accelerating our path from research innovation to manufacturable silicon.” The MLX300 tapeout follows TetraMem’s recently announced MLX200/MLX200M multi-level RRAM A-IMC SoC implemented on a commercial 22nm process, marking two successful full-mask tapeouts achieved
Exeon Analytics Introduces AgentGuard for Visibility and Threat Detection Across AI Use and Agent Activity27.10.2026 10:30:00 EET | Press release
Exeon Analytics today introduced Exeon.AgentGuard, a new AI security solution designed to give organizations visibility into approved and shadow AI use, autonomous agent activity and the data flows created through connected tools and external services. Building on its expertise in AI-driven behavioral analytics and threat detection, Exeon expands its cybersecurity capabilities to address emerging risks associated with the rapid adoption of agentic AI. Bringing visibility, addressing data leakage and rogue AI agent behavior As enterprises increasingly adopt AI agents, maintaining visibility into their activities becomes critical. Whether operating autonomously or on behalf of employees, organizations need to understand what AI agents are doing, which systems and data they access, and how they interact with external services. Exeon.AgentGuard provides security teams with visibility into AI agent activities by leveraging existing data sources, without requiring additional agents or comple
Former Nokia Technologies C-suite Executive Joins Sisvel to Lead Creation of New Ventures Unit27.10.2026 10:04:00 EET | Press release
Stavros Kyris has joined Sisvel to lead the formation of Sisvel Ventures, which has a wide-ranging remit to explore opportunities outside of Sisvel’s core areas of business. Kyris previously held a number of senior roles at Nokia and from 2019 until earlier this year was Chief Strategy, Financial and Operating Officer of Nokia Technologies. Before that, he spent five years as Chief of Staff to Nokia’s CEO, having formerly worked in corporate business development, strategy and M&A at the company. Sisvel Ventures will identify and develop IP-based business projects that do not sit within Sisvel’s established standard essential patent (SEP) pool licensing operation. It will draw on expertise within the broader company while functioning separately from it. Senior Sisvel executives Matteo Sabattini and Leonardo Saroni will join Kyris in building the new unit. “Sisvel Ventures is an exciting endeavour that I am delighted to help launch,” says Kyris. “Sisvel has a reputation for its bold, ent
Institutional Investors and Wealth Advisors Remain Bullish on Private Markets, With a Sharpened Focus on Liquidity: New Report From BBH Investor Services27.10.2026 10:00:00 EET | Press release
Private markets are growing in importance to investors’ overall portfolios, according to new research from Brown Brothers Harriman (BBH) Investor Services today. In BBH’s second annual Private Markets Investor Survey, over a quarter of investors say more than 30% of their investments will be allocated to private markets strategies in the next five years. Most investors (84%) plan to increase their private markets investments within the next two years, with private equity ranking as the top target for new investment (54%), up 16 points from last year, followed by private credit (44%), up 20 points year-over-year. The survey captures the views of 500 institutional investors and wealth advisors in the United States, the United Kingdom, Germany, Switzerland, and Japan. Liquidity emerges as a top priority for investors in this year’s report. Investors signaled that their preferred window for capital deployment in private markets is four to six years, followed by preference for an even short
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom